[1] Block T,Mehta A S,London W T. Hepatocellular carcinoma of the liver. Cancer Biomark,2010,9(1-6):375-383. [2] 吴力群,王祖森,胡维昱,等. 528例原发性肝细胞癌患者肝切除术后1年生存分析. 中华普通外科杂志,2012,27(2):92-95. [3] 王红阳. 肝癌诊断与预后判断的分子标志物. 中华肝脏病杂志,2011,19(4):241-243. [4] Ju J,Jiang J,Fesler A. miRNA:the new frontier in cancer medicine. Future Med Chem,2013,5(9):983-985. [5] Li J,Wang Y,Yu W,et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun,2011,406(1):70-73. [6] 吴育连,苏昆仑,董鑫,等. 肝癌切除术后早/晚期复发的危险因素与治疗. 中华肝胆外科杂志,2006,12(6):370-373. [7] Moriguchi M,Takayama T,Higaki T,et al. Early cancer-related death after resection of hepatocellular carcinoma. Surgery,2012,151(2):232-237. [8] 王洁,孟运运,汪茂荣. 血清AFP,GGT-Ⅱ和GGT联合检测诊断原发性肝癌的价值探讨. 实用肝脏病杂志,2012,15(6):545-547. [9] 王寿明,高蕾,于乐成,等. 甲胎蛋白异质体对肝癌诊断及疗效评估价值研究进展. 实用肝脏病杂志,2011,14(6):479-481. [10] Mitchell PS,Parkin RK,Kroh EM,et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A,2008,105(30):10513-10518. [11] Pineau P,Volinia S,Mcjunkin K,et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A,2010,107(1):264-269. [12] Di Leva G,Gasparini P,Piovan C,et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst,2010,102(10):706-721. [13] Kawaguchi T,Komatsu S,Ichikawa D,et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer,2013,108(2):361-369. [14] le Sage C,Nagel R,Egan D A,et al. Regulation of the p27(Kip1)tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J,2007,26(15):3699-3708. [15] 雷永红,吕文平,王海,等.肝细胞癌患者血清miR-221和miR-122的检测及其临床意义.河北医科大学学报,2013,34(5):522-525. |